Assessment of lung function parameters in patients with COPD on triple therapy with Trimbow extra-fine pMDI (TefpMDI) for 16 weeks – a multicenter observational study. (ERS 2026) - May 30, 2026 - Abstract #PA351; Pres time: Sep 6, 2026; 08:00 AM - 09:30 AM; Location: PS-11; Board Number: 12; "The group of patients with potential better response to therapy was identified. Although some of the results could be biased due to the open label design the data showed improvement regarding efficacy and tolerability of triple therapy in real life."
Clinical • Observational data • Cardiovascular • Chronic Obstructive Pulmonary Disease • Hypertension • Immunology • Respiratory Diseases
|
|
N. Kyuchukov; N. Rodopska; Z. Ivanova; Y. Ivanov
|